Form 4: TriSalus Life Sciences Director Wahlstrom Increases Common Stock Holdings Following Preferred Stock Conversion Price Reset

Mats Wahlstrom, a director and 10% owner of TriSalus Life Sciences, reports an increase in potential common stock holdings due to a reset in the conversion price of Series A Convertible Preferred Stock.

Summary

• On February 10, 2025, Mats Wahlstrom, a director and 10% owner of TriSalus Life Sciences, experienced a reset in the conversion price of his Series A Convertible Preferred Stock.
• This reset, according to the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed on August 10, 2023, resulted in an increase in the number of common stock shares issuable upon conversion.
• The conversion price was reset to $5.277 per share.
• As a result, the preferred stock is now convertible into 94,750 shares of common stock.
• The reporting person indirectly owns these securities through Leonard Capital LLC, sharing voting and investment discretion with their spouse.
• All outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing indicating a procedural adjustment to existing securities. The conversion price reset is a neutral event, but the increased potential common stock holdings could be viewed slightly positively.

Positives

• The conversion price reset allows for a greater number of common shares to be issued upon conversion of the preferred stock, potentially increasing the reporting person's stake in the company.

Future Outlook

The preferred stock is convertible into common stock at any time at the Reporting Person's election, and all outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027.

Industry Context

This filing reflects standard insider reporting requirements related to changes in beneficial ownership of company stock, which is common in the biotech and pharmaceutical industries.

Stakeholder Impact

• Shareholders may see a slight dilution of their ownership if the preferred stock is converted to common stock.

Key Dates

Keywords

TriSalus Life Sciences, Series A Convertible Preferred Stock, Common Stock, Beneficial Ownership, Form 4, Wahlstrom, Conversion Price Reset